
Paolo Tarantino/X
Jun 5, 2025, 08:58
Paolo Tarantino: Dato-DXd is the Latest ADC to be Approved for Treating HR+/HER2- MBC
Paolo Tarantino, 2025 Yvonne ‘Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Dato-DXd is the latest ADC to be approved for treating HR+/HER2- MBC, joining two other topo1 ADCs (T-DXd, SG).
How should we sequence these agents?
We conducted multiple rounds of polling to generate consensus within the Dana-Farber Cancer Institute Breast Oncology group.
The resulting consensus document is now published.”
More posts featuring Paolo Tarantino on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 08:47
Jun 5, 2025, 07:54
Jun 5, 2025, 05:59
Jun 5, 2025, 05:45